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pected from blood stem cell transplantation, but more severe
GVHD was a matter of concern because the content of T cells
is about 10-fold higher than in aspirated marrow [14]. The
higher content of T cells and the higher content of CD34þ
CD38- stem cells may be responsible for the faster recovery of
leukocytes and platelets [3,5,8,15-17], less frequent graft
failures [9], and better immune recovery [18]. A higher
incidence of chronic GVHD was found in large retrospective
studies [19,20], but the rate and severity of acute GVHD,
incidence of relapse, and survival were not different. How-
ever, as time goes by, chronic GVHD charges toll in reducing
survival of good-risk patients. Unlike these patients with
nonmalignant or slowly progressivemalignant disease, those
with acute leukemia and progressive disease, elderly and
frail patients, and patients conditioned with reduced in-
tensity may beneﬁt from blood stem cell transplantations
and better control of leukemia with some chronic GVHD.
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Accepted 10 November 2014The paper by Rezvani et al. [1], “The Impact of Donor Age
on Outcome after Allogeneic Hematopoietic CellTransplantation” appearing in this issue and on which this
commentary is based, demonstrates that an older donor age
does not negatively affect engraftment, graft-versus-host
disease (GVHD), relapse, or mortality after blood and
marrow transplantation. The authors evaluated the periph-
eral blood progenitor cell (PBPC) product in donors over the
age of 60 years compared with that of younger donors. Their
conclusion is surprising, as it is well established that use of
younger donors, under 20 years of age, is associated with
lower rates of acute and chronic GVHD than use of donors
older than 20 years [2]. Moreover, use of umbilical cord
blood, the youngest donor source, is associated with the
lowest rate of GVHD of any donor source. Umbilical cord
blood as a donor product is limited by its high graft failure
rate, probably because of its low numbers of memory T cells,
even when high cell numbers are infused [3]. On the other
K.R. Schultz / Biol Blood Marrow Transplant 21 (2015) 1e3 3hand, PBPC donor product has the most rapid engraftment
with low levels of graft failure. The biggest concerns associ-
ated with using older donors are the possibility of increased
GVHD because of the infusion of high number of memory T
cells and B cells, a higher graft failure rate because of a lower
number of hematopoietic precursors, and a higher rate of
secondary malignancy because of shortened telomeres
associated with aging.
Previous studies suggest that age-associated changes in
the immune system include changes to B cells, innate immune
cells, and, most dramatically, to T cells. Studies on aged T cells
show a reduced diversity of the T cell antigen receptor
repertoire and a decline in naïve T cells [4]. The aging immune
system has an increased number of memory T cells and a
higher level of innate immune function. Aging of the immune
system is also associated with an increased proinﬂammatory
status and decreased levels of resting (but not activated) T
regulatory (suppressive) cells [5]. Vaccine responses by older
immune systems are also decreased when studied for
inﬂuenza vaccine response. It has been hypothesized that
cytomegalovirus is the main driving force responsible for the
emergence of the age-related hallmark changes seen in
immune parameters [4]. The current study did not see cyto-
megalovirus positivity in donors affecting engraftment,
although its impact on GVHD or relapse was not evaluated.
Chronic GVHD is the major long-term complication
associated with PBPC donor transplants compared with
other donor sources. The negative impact of donor age on the
outcome of allogeneic blood and marrow transplantation
appears mostly because of a higher incidence and severity of
GVHD, and not an effect on engraftment. One of the major
donor populations associated with development of chronic
GVHD is that of memory B cells. Aging of the immune system
appears to increase the presence of “antigen-experienced
B cells.” In mice, antigen-experienced B cells are proin-
ﬂammatory and respond strongly to Toll-like receptor (TLR)
stimulation with relatively weak responses to typical T
celledependent signals compared with younger mice.
Recently, it has been suggested that B cells play an important
role in the downregulation of B lymphopoiesis in old age [6],
and this potentially may decrease the impact of the altered T
cell repertoire and decreased regulatory T cells seen in an
aging donor.
In spite of all of these concerns, the current study does not
support any negative outcomes associated with utilizing an
older donor source. It may be that there is a plateau in
development of GVHD after peripheral blood transplantation
that does not increase after a certain donor age is reached.
Because the rate of chronic GVHD is high after pediatric PBPC
transplantation [2], it may be that at a fairly young recipient
age, the “age effect” is negated. Short-term engraftment isidentical for this group, with number of CD34þ cells the only
important factor, as for younger donor sources, as well. It is
possible that after long-term follow up, we may observe a
higher graft failure rate, but as most of the recipients are
older in this sibling transplantation trial, this factor may not
be very important. Most encouraging is the lack of an
increased development of myelodysplastic syndrome or
acute myeloid leukemia in the older donor transplantations.
Whether identical results will be seen in a much younger
recipient population, including a pediatric population, re-
mains to be seen. However, in the study by Rezvani et al., the
older donor product went into an older recipient group,
which skewed the possible outcome against the older donor
transplant (94% over 50 years compared with 68% for the
younger donor group, shown in Table 2 of the paper).
One of the biggest disadvantages of older donor utiliza-
tion may, in fact, be to the donor. There are some donor
concerns for patients receiving granulocyte colonye-
stimulating factor (G-CSF) to mobilize for PBPC. G-CSF in-
creases a hypercoagulable state, potentially resulting in an
increased rate of myocardial infarctions or strokes, a risk that
rises with age. A small portion of G-CSF normal donors also
will develop a larger spleen, which can result in splenic
rupture. An older donor may not tolerate these complica-
tions as well. Mobilizing older donors with plerixafor may
represent a better future option. Either way, the potential
availability of older donors will increase the availability of
sibling donors to recipients with a similar efﬁcacy and safety
offered by younger donors.ACKNOWLEDGMENTS
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